news
El Financiero
2026-09-25
Mexico's Cofepris Authorizes Lenacapavir for Bi-Annual HIV Prevention
Cofepris has approved the use of Lenacapavir, a long-acting antiretroviral medication for HIV pre-exposure prophylaxis (PrEP) that is administered every six months.